Preparation of endostatin-loaded chitosan nanoparticles and evaluation of the antitumor effect of such nanoparticles on the Lewis lung cancer model

References

• Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. (2004). Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release 100:5–28
   PubMed Web of Science ®Google Scholar
• Ahmed TA, Aljaeid BM. (2016). Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Dev Ther 10:483–507
   PubMed Web of Science ®Google Scholar
• Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. (2010). Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev 62:59–82
   PubMed Web of Science ®Google Scholar
• Celik I, Surucu O, Dietz C, et al. (2005). Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65:11044–50
   PubMed Web of Science ®Google Scholar
• Chen W, Hu S. (2011). Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers. Int J Nanomed 6:1535–41
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhang L, Song Y, et al. (2015). Hierarchical targeted hepatocyte mitochondrial multifunctional chitosan nanoparticles for anticancer drug delivery. Biomaterials 52:240–50
   PubMed Web of Science ®Google Scholar
• Cui C, Mao L, Chi Z, et al. (2013). A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther 21:1456–63
   PubMed Web of Science ®Google Scholar
• Dong XP, Xiao TH, Dong H, et al. (2013). Endostar combined with cisplatin inhibits tumor growth and lymphatic metastasis of Lewis lung carcinoma xenografts in mice. Asian Pac J Cancer Prev 14:3079–83
   PubMedGoogle Scholar
• Du Y, Zhang Q, Jing L, et al. (2015). GX1-conjugated poly(lactic acid) nanoparticles encapsulating Endostar for improved in vivo anticolorectal cancer treatment. Int J Nanomed 10:3791–802
   PubMed Web of Science ®Google Scholar
• Fan J, Du J, Wu J, et al. (2015). Antitumor effects of different administration sequences of cisplatin and Endostar on Lewis lung carcinoma. Oncol Lett 9:822–8
   PubMed Web of Science ®Google Scholar
• Folkman J, Browder T, Palmblad J. (2001). Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 86:23–33
   PubMed Web of Science ®Google Scholar
• Folkman J. (2006). Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312:594–607
   PubMed Web of Science ®Google Scholar
• Fu XH, Li J, Zou Y, et al. (2011). Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft. Cancer Lett 312:109–16
   PubMed Web of Science ®Google Scholar
• Han B, Xiu Q, Wang H, et al. (2011). A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol 6:1104–9
   PubMed Web of Science ®Google Scholar
• Hu S, Zhang Y. (2010). Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation. Int J Nanomed 5:1039–48
   PubMed Web of Science ®Google Scholar
• Karagozlu MZ, Kim SK. (2014). Anticancer effects of chitin and chitosan derivatives. Adv Food Nutr Res 72:215–25
   PubMedGoogle Scholar
• Katas H, Raja MA, Lam KL. (2013). Development of chitosan nanoparticles as a stable drug delivery system for protein/siRNA. Int J Biomater 2013:146320
   PubMedGoogle Scholar
• Kim JY, Choi WI, Kim YH, Tae G. (2013). Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier. Biomaterials 34:1170–8
   PubMed Web of Science ®Google Scholar
• Kisker O, Becker CM, Prox D, et al. (2001). Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61:7669–74
   PubMed Web of Science ®Google Scholar
• Kuo CJ, Farnebo F, Yu EY, et al. (2001). Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 98:4605–10
   PubMed Web of Science ®Google Scholar
• Kuroiwa M, Takeuchi T, Lee JH, et al. (2003). Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma. J Pediatr Surg 38:1499–505
   PubMed Web of Science ®Google Scholar
• Ling Y, Yang Y, Lu N, et al. (2007). Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361:79–84
   PubMed Web of Science ®Google Scholar
• Ma X, Yao Y, Yuan D, et al. (2012). Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One 7:e53449
   PubMed Web of Science ®Google Scholar
• Maeda Y, Kimura Y. (2004). Antitumor effects of various low-molecular-weight chitosans are due to increased natural killer activity of intestinal intraepithelial lymphocytes in sarcoma 180-bearing mice. J Nutr 134:945–50
   PubMed Web of Science ®Google Scholar
• Nie Y, Zhang X, Wang X, Chen J. (2006). Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin. Bioconjug Chem 17:995–9
   PubMed Web of Science ®Google Scholar
• O'reilly MS, Boehm T, Shing Y, et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–85
   PubMed Web of Science ®Google Scholar
• Pawliuk R, Bachelot T, Zurkiya O, et al. (2002). Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol Ther 5:345–51
   PubMed Web of Science ®Google Scholar
• Piras AM, Sandreschi S, Maisetta G, et al. (2015). Chitosan nanoparticles for the linear release of model cationic peptide. Pharm Res 32:2259–65
   PubMed Web of Science ®Google Scholar
• Rampino A, Borgogna M, Blasi P, et al. (2013). Chitosan nanoparticles: preparation, size evolution and stability. Int J Pharm 455:219–28
   PubMed Web of Science ®Google Scholar
• Singh R, Lillard JW. Jr. (2009). Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86:215–23
   PubMed Web of Science ®Google Scholar
• Stoll BR, Migliorini C, Kadambi A, et al. (2003). A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood 102:2555–61
   PubMed Web of Science ®Google Scholar
• Tong Y, Zhong K, Tian H, et al. (2010). Characterization of a monoPEG20000-Endostar. Int J Biol Macromol 46:331–6
   PubMed Web of Science ®Google Scholar
• Wang J, Sun Y, Liu Y, et al. (2005). Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 8:283–90
   PubMedGoogle Scholar
• Wang JJ, Zeng ZW, Xiao RZ, et al. (2011). Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomed 6:765–74
   PubMed Web of Science ®Google Scholar
• Weidner N, Semple JP, Welch WR, Folkman J. (1991). Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1–8
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. (2011). Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17:1359–70
   PubMed Web of Science ®Google Scholar
• Wu J, Wu L, Xu X, et al. (2009). Microspheres made by w/o/o emulsion method with reduced initial burst for long-term delivery of endostar, a novel recombinant human endostatin. J Pharm Sci 98:2051–8
   PubMed Web of Science ®Google Scholar
• Xu F, Ma Q, Sha H. (2007). Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment. Crit Rev Ther Drug Carrier Syst 24:445–92
   PubMed Web of Science ®Google Scholar
• Xu X, Mao W, Chen Q, et al. (2014). Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway. PLoS One 9:e107463
   PubMed Web of Science ®Google Scholar
• Zhuo W, Luo C, Wang X, et al. (2010). Endostatin inhibits tumor lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells. J Pathol 222:249–60
   PubMed Web of Science ®Google Scholar